Clari

Companies

Company case studies with full pipeline analysis, plus the TPD competitive landscape.

Massachusetts and Greater Boston case studiesUS listed issuers in this directory
Ask AI about this page

Company case studies

NASDAQ: KYMR

Kymera Therapeutics

Kymera workspaceProfile

Directed protein degradation to destroy disease

4 programs3 clinicalFounded 2016
:

Lila Sciences

Profile

Scientific Superintelligence

2 programsFounded 2023
NASDAQ: VRTX

Vertex Pharmaceuticals

Profile

Scientific innovation to create transformative medicines for serious diseases

7 programs7 clinicalFounded 1989

Competitive landscape

Sorted by therapeutic area overlap and clinical stage

Full TPD matrix
ImmunologyOncologyNeurology6 companies
Ask AI
AR
Arvinas
ARVN
Ph 3
OncologyNeurology

PROTAC® Technology · 3 clinical programs

ARV-471 (Vepdegestrant)·ER+/HER2- Breast CancerPh 3
ARV-110 (Bavdegalutamide)·Metastatic Castration-Resistant Prostate CancerPh 2
ARV-102·Parkinson's DiseasePh 1
arvinas.comSearch trials
Ask AI
C4
C4 Therapeutics
CCCC
1/2
Oncology

TORPEDO® · 3 clinical programs

CFT8919·EGFR L858R NSCLC1/2
CFT1946·BRAF V600X Solid TumorsPh 1
CFT7455·Relapsed/Refractory MM / NHL1/2
c4therapeutics.comSearch trials
Ask AI
NU
Nurix Therapeutics
NRIX
Ph 1
Oncology

DELigase™ · 2 clinical programs

NX-5948·B-cell Malignancies / CLL / MCLPh 1
NX-2127·Relapsed/Refractory B-cell MalignanciesPh 1
nurixtx.comSearch trials
Ask AI
MO
Monte Rosa Therapeutics
GLUE
Ph 1
Oncology

QuEEN® · 2 clinical programs

MRT-2359·MYC-Driven Cancers (NSCLC, SCLC)Ph 1
MGX-12·Solid Tumors (Treg depletion)Ph 1
monterosatx.comSearch trials
Ask AI
PL
Plexium
Private
Ph 1
Oncology

Molecular Glue Discovery · 1 clinical program

PLX-4545·Solid TumorsPh 1
plexium.comSearch trials
Ask AI
VI
Vividion Therapeutics
Bayer (2021)
Pre
Oncology

Chemoproteomics-guided TPD · 0 clinical programs

VVD-159·OncologyPre
vividion.comSearch trials
Ask AI
Data sources:Company investor materialsClinicalTrials.govSEC filingsPress releasesInteractive TPD matrix
Ask AI